23andMe
-
Crunch Report | Jeff Bezos Sells $1B in Amazon Stock Annually to Fund Blue Origin
The Kriesel high-performance electric converted Porsche, Jeff Bezos sells $1 billion in stock annually to fund Blue Origin, Hyperloop One completes Vegas test track and 23andMe can now let you know if you have the genes for Parkinson’s. All this on Crunch Report. Read More
-
23andMe is finally allowed to tell you if you have the genes for Parkinson’s
The Food and Drug Administration finally gave 23andMe a long sought-after green light today to sell to consumers genetic tests and their accompanying health risk reports for up to 10 diseases, including late-onset Alzheimer’s and Parkinson’s. Read More
-
Crunch Network
Advances in AI and ML are reshaping healthcare
The application of AI/ML in healthcare is reshaping the industry and making what was once impossible into a tangible reality. Read More
-
23andMe reportedly no longer working on next-gen sequencing
23andMe won’t continue with next-generation DNA sequencing and has reportedly laid off the lab working on the project. About half-a-dozen workers were laid off from the Salt Lake City, Utah-based lab, according to BuzzFeed, which first reported the news. By our own count based on LinkedIn, at least five members of the lab have been let go, including its chief medical officer, Dr. Read More
-
Color Genomics raises $45 million to provide cheaper genetic tests that detect cancer risk
Othman Laraki and Elad Gil were sitting on Twitter’s roof deck after their previous company Mixer Labs had been acquired. Gil had brought a small hard drive with him — which happened to contain data on his genome being sequenced — and Laraki wanted to take a look at the data. That led to the original hypothesis of Color Genomics: what if you could apply the same principles… Read More
-
23andMe’s Anne Wojcicki has a plan to include better genetic data from people of color
One of the first consumer genetic testing companies, 23andMe says it aims to be at the forefront in gathering genetically diverse data throughout the world. The company just launched a standalone $99 ancestry service today as a way to offer those interested in their genetic lineage the ability to trace ancestors and relatives just by spitting into a tube. Ancestral DNA is something founder… Read More
-
Crunch Network
Innovation in genomics and the future of medtech
The field of medicine is in the process of being profoundly transformed by new technologies; much of this transformation comes from exciting advances in genomics. Although genomics is relatively unknown to the general public, innovations in the field have started to make headlines: Genetic testing startup 23andMe, the “gene editing” technology CRISPR and the ambitious 100,000… Read More
-
12 women leading the life sciences movement in Silicon Valley
Breakthroughs in genetic engineering, 3D printing, cloud-based science experiments, A.I. and machine learning technology have created a weird and cool new kind of cutting-edge biotech that goes beyond pharma into what just a few decades ago seemed like magical thinking. And women are leading the charge in this brave new world, especially in Silicon Valley. While there are plenty of women… Read More
-
23andMe and Women’s Health Startup Celmatix Combine Forces To Research Genes Affecting Infertility
Humans have been having humans for hundreds of thousands of years as part of our genetic drive so it seems counter-Darwinian that some genes might work against our ability to make a baby. But that is exactly what certain genes might be doing, according to women’s health startup Celmatix, and they are now working with 23andMe to hopefully figure out why. Celmatix tries to take the… Read More
Latest Crunch Report
-
Crunch Network
The Evolution Of The Biohacking Ecosystem
Silicon Valley efforts in the biology and health domains have recently seen increased public interest because of the questions around the legitimacy of Theranos’ technology and medical claims and the recent FDA approvals for a number of 23andMe’s genetic screens. These data points are just two of the most visible examples of a broad ecosystem of companies and startups in Silicon… Read More
-
FDA Clears 23andMe For Health and Carrier Status Testing
Things are looking up for 23andMe. Right off a fresh $115 million cash infusion, the Food and Drug Administration is giving the direct-to-consumer DNA company the green light to include health and carrier status, along with ancestry reports. This was not the scenario two years ago when the FDA put a moratorium on 23andMe’s ability to provide any health information associated with… Read More
-
WellPath Integrates With 23andMe, Fitbit To Customize Your Daily Supplements
These days, you can get a subscription box for just about anything. And today, that includes customized nutritional supplements. WellPath, a company that puts together customized packages of monthly nutritional supplements tailored to your specific body, has today announced integrations with 23andMe and Fitbit to get even more granular with the way that suggest products. Originally, WellPath… Read More
-
Warburg Pincus, Illumina & Sutter Hill Launch New Genomics Co. Helix With $100M
Based in San Francisco, Helix is aiming to be a central repository for personalized genetic information and provide a marketplace for applications potentially like the ones developed in Illumina’s genome-based accelerator program. Read More
-
We Asked Rock Health Founder Halle Tecco About The Future Of Digital Medicine
Health technology is becoming a big topic in 2015. We’re seeing wearable technology that can automatically upload our health data to the cloud, cellphones are becoming tools to connect us to the doctor’s office, a Google moonshot project detects cancer on an app and 23andMe has received FDA approval for at least one genetic test of a rare disease. This is now a multi-billion… Read More
-
Crunch Network
Genomics Needs A Killer App
Genomics has undergone a major shift in the last year. The drop in price in the past decade from $3B to $1K to sequence a genome is the 10X force likely to cause an inflection point in a number of health-related industries. But despite the price, right now genomics is a niche product in large part used in and promoted by academia. Read More
-
CrunchWeek: YikYak Vs. Spam, VCs Funding Coffee, Big Steps For Science Tech
Another week in tech has come and gone, bringing a fresh crop of stories for us to talk about on CrunchWeek, the show that brings a few TechCrunch writers together to talk about some of the most interesting news of the past seven days. This time, Sarah Buhr, Josh Constine and I gathered around the big white table to talk about Josh’s big story on YikYak’s controversial methods… Read More
-
FDA Authorizes 23andMe To Market Genetic Testing For Bloom Syndrome
The U.S. Food and Drug Administration has given 23andMe clearance to begin selling kits for the genetic testing of Bloom Syndrome. This is a rare recessive gene disorder that is characterized by shorter height and a predisposition to develop cancer. Parents of children with Bloom Syndrome don’t exhibit any symptoms of the disorder. Read More
-
23andMe Ceases Health-Focused Gene Testing, Still Offers Raw Genetic Data And Ancestry Reports
After the Food and Drug Administration ordered that 23andMe suspend use of its at-home gene testing kits, based on the government organization’s belief that it constitutes a medical device and thus requires further examination and testing before it can be provided for sale. 23andMe followed up to that bombshell with the news that it would be working with the FDA to try to resolve the… Read More
-
If Inaccuracy Were Illegal, The Feds Would Have To Regulate Most Health Gadgets
I wore a calorie counter armband from BodyMedia that told me I was burning over 3,000 calories a day. If that were true, I would be emaciated enough to play Gollum in the next Lord Of The Rings sequel. The accuracy of consumer health gadgets varies widely, yet this hasn’t stopped the FDA from suspending popular genetic testing company 23andMe over concerns about the quality of their… Read More
-
DNA Testing Startup 23andMe Hits A Snag As FDA Shuts Down Sales Of Home Testing Kit
The U.S. Food and Drug Administration has ordered 23andMe, the genomic startup co-founded by Anne Wojcicki, Linda Avey and Paul Cusenza in 2006, to stop selling its at-home DNA testing kits as of November 22. As Bloomberg reports, a letter from the FDA sent to the company made public today classifies the kit as a medical device and outlines that it required regulatory approval before being… Read More
Message Us